STOCK TITAN

Pulmatrix Q3 2026 net loss widens to $1.21M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Pulmatrix, Inc. (PULM) reported a third-quarter 2026 net loss of $1.213 million, compared with $877,000 a year earlier. General and administrative expense was $1.220 million, versus $858,000, primarily due to merger-related legal and professional services; research and development expense was $1,000, compared with $8,000. For the first nine months, net loss was $3.421 million, versus $4.234 million in 2025.

The proposed merger with Eos SENOLYTIX is currently anticipated to close in November 2026, subject to Nasdaq approval of listing the merger shares, completion of the reverse stock split approved by stockholders on October 26, 2026, and customary closing conditions. Stockholders approved the merger, and the Form S-4 registration statement became effective September 25, 2026. At September 30, Pulmatrix had $1.398 million in cash and cash equivalents and $700,000 in restricted cash. Pulmatrix anticipates that its cash position, based on current operational efficiencies and prioritization of spending, is sufficient to fund operations at least through the anticipated merger closing.

All clinical development is on hold while Pulmatrix seeks to license or monetize its clinical assets.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 1 point

How the balance works

Positive

  • Moderate pointNine-month net loss was $3.421 million, versus $4.234 million in 2025.

Negative

  • Major pointClinical development is on hold during efforts to license or monetize assets.

Filing Explained

At September 30, 2026, $1.398 million in cash and equivalents equaled 167 days of the latest reported quarterly operating cash outflow.

The filing leaves the Eos merger proposed, not completed; the September 30, 2026 balance sheet lists $700,000 as restricted cash, which would become unrestricted upon merger completion or under the merger agreement’s terms, so it was not yet unrestricted.

At September 30, 2026, $1.398 million in cash and equivalents equaled 167 days of the latest reported quarterly operating cash outflow at that rate; this is a backward-looking comparison, not a forecast.

Sources and calculations
  • Available liquidity against the last reported quarterly operating outflow, in days at that rate $1,398,000 / ($770,000 / 92) = 167 days
Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Third-quarter net loss $1.213 million Three months ended September 30, 2026; $877,000 in the same period of 2025
General and administrative expense $1.220 million Three months ended September 30, 2026; $858,000 in the same period of 2025
Research and development expense $1,000 Three months ended September 30, 2026; $8,000 in the same period of 2025
Nine-month net loss $3.421 million Nine months ended September 30, 2026; $4.234 million in the same period of 2025
Cash and cash equivalents $1.398 million As of September 30, 2026
Restricted cash $700,000 As of September 30, 2026; would become unrestricted following merger consummation or in accordance with the Merger Agreement
Private placement gross proceeds $1.0 million Raised March 26, 2026, through a private placement with an Eos affiliate
iSPERSE™ technical
"using its patented iSPERSE™ technology"
MitoXcel™ technical
"using the MitoXcel™ platform"
Series B Convertible Preferred Stock financial
"issuance and sale of its newly designated Series B Convertible Preferred Stock"
Series B convertible preferred stock is a class of shares sold during a later-stage private financing that combines features of a loan and common stock: it usually pays priority dividends or has a priority claim if the company is sold, and it can be converted into common shares under predefined rules. Investors care because these shares affect ownership stakes and payout order—like having a reserved place in line and a ticket that can turn into regular ownership—so they influence potential returns and dilution for other shareholders.
restricted cash financial
"$0.7 million in restricted cash that would become unrestricted"
Cash that a company holds but cannot use for day-to-day operations because it is set aside for a specific purpose—such as meeting loan covenants, serving as collateral, funding an escrow, or complying with regulations. Like money in a locked savings account earmarked for a bill, restricted cash reduces the cash available to run the business and pay dividends or debts, so investors treat it differently when assessing a company’s true short-term financial strength.
going concern financial
"continue as a going concern within one year"
Going concern is the accounting assumption that a company will keep operating and meeting its obligations for the foreseeable future. The phrase matters most when a company or its auditors disclose substantial doubt about it, a formal warning that the business may not have enough resources to continue without raising money, restructuring, or selling assets. That language in a filing or press release signals elevated financial risk.
gerotherapeutic peptides medical
"gerotherapeutic peptides targeting mitochondrial dysfunction"
Third-quarter net loss $1.213 million versus $877,000 for the three months ended September 30, 2025
General and administrative expense $1.220 million versus $858,000 for the three months ended September 30, 2025
Research and development expense $1,000 versus $8,000 for the three months ended September 30, 2025
Nine-month net loss $3.421 million versus $4.234 million for the nine months ended September 30, 2025
Cash and cash equivalents $1.398 million versus $4.088 million as of December 31, 2025
Guidance

Pulmatrix anticipates that its cash position, based on current operational efficiencies and prioritization of spending, is sufficient to fund operations at least through the anticipated closing of the proposed merger with Eos SENOLYTIX.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much did PULM raise in its private placement with an Eos affiliate?

On March 26, 2026, Pulmatrix entered into a securities purchase agreement with an Eos affiliate for a private placement of newly designated Series B Convertible Preferred Stock, raising aggregate gross proceeds of $1.0 million.

How can Pulmatrix's restricted cash become unrestricted?

Pulmatrix said the $700,000 in restricted cash at September 30, 2026, would become unrestricted following consummation of the merger or in accordance with the Merger Agreement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001574235 0001574235 2026-11-17 2026-11-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 17, 2026

 

PULMATRIX, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-36199   46-1821392

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

945 Concord Street, Suite 1217

Framingham, MA 01701

(Address of principal executive offices) (Zip Code)

 

(888) 355-4440

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of exchange on which registered
Common Stock, par value $0.0001 per share   PULM   The NASDAQ Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

 

On November 17, 2026, Pulmatrix, Inc. issued a press release announcing its financial results for the third fiscal quarter ended September 30, 2026, and provided a corporate update. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

 

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, being furnished pursuant to Item 2.02, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
     
99.1   Press Release dated November 17, 2026*
104   Cover Page Interactive Data File (formatted as Inline XBRL)

 

* This exhibit is furnished pursuant to Item 2.02 and shall not be deemed to be “filed.”

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  PULMATRIX, INC.
     
Date: November 17, 2026 By: /s/ Peter Ludlum
    Peter Ludlum
    Interim Chief Executive Officer and Interim Chief Financial Officer

 

 

 

 

Exhibit 99.1

 

 

Pulmatrix Announces Third Quarter 2026 Financial Results and Progress on Merger

 

Merger with Eos SENOLYTIX expected to close by end of the year

 

Framingham, Mass., November 17, 2026 – Pulmatrix, Inc. (“Pulmatrix”, the “Company” or “our”) (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, today announced its third quarter financial results for 2026 and provided a corporate update related to the merger agreement with Eos SENOLYTIX announced at the end of the first quarter of 2026.

 

Peter Ludlum, Interim Chief Executive Officer of Pulmatrix, commented, “Our focus in the third quarter and beyond has been to advance steps towards completing the proposed merger with Eos SENOLYTIX, a privately held biotechnology company developing novel gerotherapeutic peptides targeting mitochondrial dysfunction in aging-related diseases using the MitoXcel™ platform. To that end, we have obtained SEC effectiveness on our registration statement on Form S-4 in relation to the merger as well as approval from our stockholders on the proposed merger. We anticipate closing the proposed merger by the end of the year.”

 

Proposed Merger with Eos SENOLYTIX

 

As previously reported, on March 26, 2026, the Company entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Eos SENOLYTIX, Inc. (“Eos”), pursuant to which a wholly owned subsidiary of the Company will merge with and into Eos, with Eos surviving as a wholly owned subsidiary of the Company (the “Merger”). The proposed Merger is currently anticipated to close in November 2026, subject to Nasdaq’s approval of the listing of the shares of the Company’s common stock to be issued in connection with the Merger, the completion of the reverse stock split approved by the Company’s stockholders on October 26, 2026, and other customary closing conditions. If the proposed Merger is completed, the business of Eos will continue as the business of the combined company.

 

In connection with the entry into the Merger Agreement, on March 26, 2026, the Company announced that it entered into a securities purchase agreement with an affiliate of Eos for the issuance and sale in a private placement of its newly designated Series B Convertible Preferred Stock, raising aggregate gross proceeds of $1.0 million.

 

Additional information about the Merger Agreement was previously disclosed in a registration statement on Form S-4 (File No. 333-297342) initially filed with the Securities and Exchange Commission (the “SEC”) on July 9, 2026, as amended, and declared effective on September 25, 2026.

 

Pulmatrix Seeks to Out-license or Monetize its Clinical Assets

 

iSPERSE™ Technology

 

●iSPERSE™, also licensed to MannKind Corporation and Cipla Technologies for certain fields of use, utilizes particles that are engineered with a small, dense and dispersible profile to exceed the performance of traditional dry powder particles as the iSPERSE™ particles have the dispersibility advantages of porous engineered particles. Pulmatrix believes this results in superior drug delivery compared to traditional oral and injectable forms of treatment for certain diseases.

 

 
 

 

 

●As of September 30, 2026, Pulmatrix’s patent portfolio related to iSPERSE™ included approximately 143 granted patents, 17 of which are U.S.-granted patents, plus approximately 47 pending patent applications in the U.S. and other jurisdictions.

 

●In July 2026, Pulmatrix was awarded a patent in India with claims encompassing PUR1900 resulting from a patent hearing in India.

 

PUR1900

 

●PUR1900, has been approved to proceed to a Phase 3 in India conducted by our partner Cipla. This is the Company’s inhaled iSPERSE™ formulation of the antifungal drug itraconazole being investigated for various indications. The Company and its partner, Cipla, wound down a Phase 2b trial that the Company was operating in 2024. Cipla has continued clinical development outside the United States, and completed their Phase 2 study in India, published positive results and has been approved by India’s Central Drug Standard Control Organization to proceed with a Phase 3 clinical trial, which Cipla currently expects to commence in 2026.

 

●Pulmatrix will receive 2% royalties on any potential future net sales by Cipla outside the United States should Cipla successfully market PUR1900 outside the United States. Within the United States, the Company and Cipla will seek to monetize PUR1900 for indications where an orally inhaled antifungal may provide a therapeutic benefit or fulfill an unmet medical need.

 

PUR3100

 

●PUR3100, a Phase 2-ready asset, is an orally inhaled dihydroergotamine (“DHE”) engineered with Pulmatrix’s iSPERSE™ dry powder inhalation technology for the treatment of acute migraine has a Food and Drug Administration acceptance of an Investigational New Drug (“IND”) application for PUR3100 and receipt of a “study may proceed” letter to proceed with a Phase 2 study. The IND includes a Phase 2 clinical protocol where safety and preliminary efficacy of PUR3100 will be investigated in patients with acute migraine.

 

●The Phase 2 IND builds on the Phase 1 trial results of PUR3100, which were published in 2024 in the peer-reviewed publication, Headache: The Journal of Head and Face Pain. The study showed that PUR3100 achieved peak exposures in the targeted therapeutic range and time to maximum concentration occurred at five minutes after dosing at all dosing levels. The PUR3100 dose groups also showed a lower incidence of nausea and no vomiting compared to observations of nausea and vomiting in the intravenously (“IV”) administered DHE dose group.

 

PUR1800

 

●PUR1800 is a Narrow Spectrum Kinase Inhibitor (“NSKI”), engineered with our iSPERSE™ technology, for the treatment of acute exacerbations in chronic obstructive pulmonary disease (“AECOPD”). In 2023, Pulmatrix presented complete results from a Phase 1b study of PUR1800 for AECOPD, indicating PUR1800 was well-tolerated with no observed safety signals. The topline data, along with the results from chronic toxicology studies, support the continued development of PUR1800 for the treatment of AECOPD and other inflammatory respiratory diseases.

 

●In 2024, Pulmatrix published an abstract titled “Ex vivo evaluation of the potential for Narrow Spectrum Kinase inhibitors as a treatment for Idiopathic Pulmonary Fibrosis”.

 

Third Quarter 2026 Financial Results

 

Research and development expenses were less than $0.1 million for both the three months ended September 30, 2026, and 2025. All clinical development is currently on hold while the Company works to license or monetize its clinical assets.

 

General and administrative expenses increased approximately $0.4 million to $1.2 million for the three months ended September 30, 2026, compared to $0.9 million for the three months ended September 30, 2025. The increase was primarily due to merger-related activities, including legal and professional services.

 

The Company’s total cash and cash equivalents balance as of September 30, 2026, was $1.4 million, in addition to $0.7 million in restricted cash that would become unrestricted following consummation of the Merger or in accordance with the terms of the Merger Agreement, as compared to $4.1 million as of December 31, 2025. The Company’s unaudited financial statements were prepared assuming that the Company will continue as a going concern within one year after the date such financial statements are issued. The Company anticipates that its cash position, based on current operational efficiencies and prioritization of spending, is sufficient to fund its operations at least through the anticipated closing of the proposed Merger with Eos.

 

 
 

 

 

PULMATRIX, INC.

Consolidated Balance Sheets

(in thousands, except share and per share data)

 

  

September 30,

2026

  

December 31,

2025

 
   (unaudited)     
Assets          
Current assets:          
Cash and cash equivalents  $1,398   $4,088 
Restricted cash   700      
Prepaid expenses and other current assets   258    41 
Total current assets   2,356    4,129 
Long-term restricted cash   7    10 
Total assets  $2,363   $4,139 
Liabilities and stockholders’ equity          
Current liabilities:          
Accounts payable  $815   $272 
Accrued expenses and other current liabilities   202    57 
Total current liabilities   1,017    329 
Total liabilities   1,017    329 
Stockholders’ equity:          
Preferred stock, $0.0001 par value — 500,000 shares authorized; 6,746 shares designated Series A Convertible Preferred Stock: no shares issued and outstanding at September 30, 2026 and December 31, 2025; 1,100 shares designated Series B Convertible Preferred Stock: 1,000 shares issued and outstanding at September 30, 2026, and no shares issued and outstanding at December 31, 2025   987    - 
Common stock, $0.0001 par value — 200,000,000 shares authorized; 3,652,285 shares issued and outstanding at September 30, 2026, and December 31, 2025   -    - 
Additional paid-in capital   306,098    306,128 
Accumulated deficit   (305,739)   (302,318)
Total stockholders’ equity   1,346    3,810 
Total liabilities and stockholders’ equity  $2,363   $4,139 

 

 
 

 

 

PULMATRIX, INC.

Consolidated Statements of Operations

(in thousands, except share and per share data)

(unaudited)

 

  

Three Months Ended

September 30,

  

Nine Months Ended

September 30,

 
   2026   2025   2026   2025 
Operating expenses:                    
Research and development  $1   $8   $6   $41 
General and administrative   1,220    858    3,553    4,220 
Total operating expenses   1,221    866    3,559    4,261 
Loss from operations   (1,221)   (866)   (3,559)   (4,261)
Other income (expense):                    
Interest income   8    30    30    124 
Fair value adjustment of warrants   -    -    -    67 
Other income (expense), net   -    (41)   108    (164)
Total other income (expense), net   8    (11)   138    27 
Net loss  $(1,213)  $(877)  $(3,421)  $(4,234)
Dividends accrued on Series B Convertible Preferred Stock   (21)   -    (37)   - 
Net loss attributable to common stockholders   (1,234)   (877)   (3,458)   (4,234)
Net loss per share attributable to common stockholders – basic and diluted  $(0.34)  $(0.24)  $(0.95)  $(1.16)
Weighted average common shares outstanding – basic and diluted   3,652,285    3,652,285    3,652,285    3,652,285 

 

 
 

 

 

About Pulmatrix, Inc.

 

Pulmatrix is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology. The Company’s proprietary product pipeline includes treatments for central nervous system (“CNS”) disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease (“COPD”) and allergic bronchopulmonary aspergillosis (“ABPA”). Pulmatrix’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE™, which seeks to improve therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes. For more on the Company’s inhaled product candidates please visit:

 

https://www.pulmatrix.com/pipeline.html.

 

About Eos SENOLYTIX, Inc.

 

Eos SENOLYTIX, based in Houston, Texas, develops MitoXcel geropeptides as FDA-regulated therapeutics for obesity, sarcopenia and other age-related disorders. The Company holds an exclusive license to the MitoXcel platform from its parent company, SENOTHERAPEUTIX, Inc. (f/k/a GEROTHERAPEUTIX), for its therapeutic field. For more information, visit eossenolytix.com.

 

Forward-Looking Statements

 

Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the federal securities laws. Such forward-looking statements include, but are not limited to, statements other than statements of historical fact and may be identified by words such as “anticipates,” “assumes,” “believes,” “can,” “could,” “estimates,” “expects,” “forecasts,” “guides,” “intends,” “is confident that,” “may,” “plans,” “seeks,” “projects,” “targets,” and “would,” and their opposites and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management and include, but are not limited to, the Merger, including the expected timing of closing and the ability to satisfy the remaining closing conditions, including Nasdaq listing approval; the expected Merger-associated financings and the combined company’s ability to advance its pipeline through key clinical milestones; the Company’s ability to satisfy Nasdaq’s Continued Listing Standards; the Company’s anticipated cash position following the Merger; and the use of proceeds from the private placement and conversion of the Series B Preferred Stock. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the consummation of any other potential reverse merger transaction in the future, among others; the Company’s ability to divest its clinical assets on terms favorable to the Company, or at all, the Company’s ability to maintain compliance with the listing standards of the Nasdaq Capital Market; the Company’s ability to continue as a going concern, the Company’s ability to conduct its business and raise capital in the future when needed; delays in planned clinical trials; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the Company’s ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; the ability to secure and enforce legal rights related to the Company’s products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to the Company, including the proposed Merger with Eos, is set forth in the Company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K, as may be supplemented or amended by the Company’s Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

 

Investor Contact:

 

Chuck Padala

Managing Director

LifeSci Advisors

646-627-8390

chuck@lifesciadvisors.com

 

 

 

Filing Exhibits & Attachments

5 documents

Keep reading